Key Takeaways Altimmune's pemvidutide showed MASH resolution without worsening fibrosis in a phase IIb study.ALT's dual glucagon and GLP-1 pathways aim to target liver fat, inflammation and weight loss togetherALT plans a 1,800-patient phase III MASH trial in 2026 with FDA-aligned endpoints for approvalAltimmune (ALT) is advancing pemvidutide as a differentiated approach to serious liver diseases where effective options remain limited.The key question for investors is whether pemvidutide’s dual-pathway biol ...